WeVote
Log In

Bill

Bill

HR 679

Nichols, Wesley; commend

2025-2026 Regular Session Introduced by Jan Jones

HR 679 seeks to nullify FDA's January 2023 mifepristone REMS changes and bars the HHS from enforcing any similar REMS, reshaping access, safety, and regulation.

House Read and Adopted
0
WeVote Research Nonpartisan
Bill Summary · HR 679

Summary of HR 679 (materials provided)

Note on source materials: The documents you provided contain two distinct texts under the label “HR 679.” One is statutory language that would nullify certain FDA risk-evaluation-and-mitigation-strategy (REMS) modifications for the drug mifepristone. The other is a ceremonial state House resolution recognizing Wesley Nichols for 25 years of service as a capitol photographer. Below are clear, separate summaries of each item, with key provisions, affected parties, and procedural notes.

A. Text nullifying FDA REMS modifications for mifepristone

(Identified in the packet as “Introduced in House” — statutory/regulatory language)

Purpose / intent

  • To nullify the Food and Drug Administration’s January 2023 modifications to the risk evaluation and mitigation strategy (REMS) for mifepristone (the statutory citation in the text is 21 U.S.C. 355–1) and to bar the Department of Health and Human Services (HHS) from establishing or enforcing any REMS provisions for mifepristone that are “substantially similar” to those nullified modifications.

Key provisions

  • Subsection (a): Declares the FDA’s January 2023 REMS modifications for mifepristone null and void.
  • Subsection (b): Prohibits the Secretary of HHS, or any head of any HHS office/agency, from establishing, implementing, or enforcing any REMS provision for mifepristone that is substantially similar to the nullified 2023 modifications.

Who/what would be affected

  • Federal regulators: FDA and HHS authorities responsible for drug safety oversight and REMS design/implementation.
  • Drug manufacturers and distributors of mifepristone: changes could alter compliance and distribution requirements.
  • Healthcare providers, pharmacies, and patients: any change to REMS affects how mifepristone can be prescribed, dispensed, and accessed.
  • Legal/regulatory environment: would directly limit HHS/FDA regulatory discretion regarding REMS for this specific drug and could prompt litigation over agency authority.

Procedural/timeline aspects (as provided)

  • Introduced: January 23, 2025
  • Referred to the House Committee on Energy and Commerce (same day)

Potential implications

  • A statutory nullification would reverse the specified FDA action and constrain future agency rulemaking for mifepristone REMS. That could change access, distribution, and safety-reporting frameworks for the drug. It would raise separation-of-powers and administrative-law issues (e.g., limits on agency discretion), and could lead to litigation if agencies or stakeholders contest the nullification or its scope.

B. House Resolution recognizing Wesley Nichols (Georgia-style ceremonial resolution)

(LC 112 3465 / House Resolution text introduced by Representative Jan Jones of the 47th)

Purpose / intent

  • A ceremonial resolution honoring Wesley Nichols on the occasion of his 25th year as a member of the Capitol Press Corps and lead capitol photographer for Georgia Public Broadcasting’s “Lawmakers.”

Key provisions / content

  • Recognizes Nichols’ 25 years of service documenting Georgia’s legislative process.
  • Notes his role as lead capitol photographer for GPB’s Lawmakers, his exclusive interviews, press coverage, and relationships with legislators.
  • Praises his commitment to journalistic excellence, transparency in reporting, and personal qualities (integrity, fairness, etc.).
  • Directs the Clerk of the Georgia House of Representatives to provide an appropriate copy of the resolution to Wesley Nichols.

Who/what would be affected

  • Primarily an honorary recognition for Wesley Nichols and the Capitol Press Corps community; no regulatory or budgetary effects.

Procedural/timeline aspects (as provided)

  • Filed / First readers and House hopper: March–April 2025 entries listed
  • Placed on Congratulations & Memorial Resolutions Calendar: April 9, 2025
  • Laid before the House, Adopted, and Reported enrolled: April 9, 2025

Final note

The provided packet mixes two unrelated measures under the same identifier. If you want a single consolidated product for one of these items, tell me which (A: the REMS/mifepristone statutory language, or B: the Wesley Nichols commendation), and I will expand the summary or prepare briefing materials tailored to that text.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.